Table 2.

Associations between baseline risk factors and baseline LVMI, LVVI, and fractional shortening

ParameterIncrement or Reference CategoryUnadjusted (β [SE])PAdjusted, Model 1 (β [SE])PModel 2 (β [SE])P
LVMI
    femaleMale−9.28 (2.86)<0.01−9.35 (2.86)<0.01−10.52 (2.95)<0.01
    BMI1.5 kg/m2−1.02 (0.38)<0.01−1.04 (0.39)<0.01
    SBP13.5 mmHg3.01 (0.90)<0.012.69 (0.90)<0.01
    DBP10.0 mmHg2.95 (1.11)<0.013.14 (1.13)<0.01
    Hb0.4 g/dl−1.00 (0.46)0.03
    serum albumin0.1 g/dl−0.98 (0.46)0.03−1.17 (0.47)0.01
    BNP76 ng/ml−0.93 (0.12)<0.010.93 (0.11)<0.010.87 (0.13)<0.01
    Troponin T0.005 ng/ml0.26 (0.10)<0.010.20 (0.10)0.04
LVVI
    femaleMale−3.60 (1.76)0.04−3.54 (1.76)0.04
    hypertensive renal diseaseGN−7.86 (3.43)0.02−7.63 (3.53)0.03−8.01 (3.62)0.02
    dialysis duration1.5 months−0.58 (0.26)0.03−0.56 (0.30)0.03−0.61 (0.28)0.04
    catheterFistula−7.02 (2.84)0.01−6.22 (2.87)0.03
    BMI1.5 kg/m2−1.10 (0.23)<0.01−1.07 (0.24)<0.01−0.81 (0.29)<0.01
    interdialytic weight gain0.7 kg−1.22 (0.58)0.04−1.40 (0.59)0.02
    BNP76 ng/ml0.33 (0.08)<0.010.33 (0.08)<0.010.31 (0.08)<0.01
Fractional shortening
    age6.3 years0.34 (0.14)0.020.32 (0.14)0.02
    femaleMale2.16 (0.70)<0.012.11 (0.70)<0.012.02 (0.78)<0.01
    diabetic renal diseaseGN2.41 (1.04)0.02
    polycystic kidney diseaseGN2.60 (1.31)0.05
    BNP76 ng/ml−0.07 (0.03)0.04−0.06 (0.03)0.04−0.08 (0.03)<.01
    Troponin T0.005 ng/ml0.05 (0.02)0.040.06 (0.02)0.040.07 (0.03)<0.01
  • Parameter estimates for continuous variables were computed for intervals equal to one half the interquartile range. All of the variables shown in Table 1 were considered; only those with the P < 0.05 are shown. Model 1 adjusted for age and gender; model 2 adjusted for age, gender, and variables with P < 0.05 in model 1. GN, glomerulonephritis.